Surmodics Announces the Clinical Use of Pounce LP Thrombectomy System

Surmodics, leading provider of medical device and in vitro diagnostic technologies, announced the successful early clinical use of its Pounce LP (Low Profile) Thrombectomy System. In June of 2023, the Pounce LP Thrombectomy System received FDA clearance and is currently in limited market evaluation (LME), with plans for a full commercial launch. 
 
The Pounce System is the first mechanical thrombectomy device for the removal of acute-to chronic thrombi and emboli in occluded peripheral arteries without using capital equipment or aspiration and minimizing the use of thrombolytics. This system was introduced in 2021 and cleared by the FDA in June of 2023. It is designed for use in vessels 3.5 mm to 6 mm in diameter.
 
The Pounce LP System complements the original Pounce System. Pounce LP is indicated for use in vessels typically found below the knee in ranging from 2 mm to 4 mm in diameter. 
 
“In our first use of the device, the Pounce LP Thrombectomy System performed exceptionally well in helping our team restore blood flow to the foot for a limb-threatened patient,” said vascular surgeon Dr. Lucas Ferrer Cardona. “Using the device, we promptly removed acute and subacute thrombus from the mid-peroneal artery below the knee with no adjunctive use of thrombolytics and no embolization. Thrombi or emboli in below-the-knee vessels have traditionally been very challenging to remove. I believe this device holds great promise in filling a major gap in our treatment algorithm.”
 
Dr. Elizabeth Genovese is a vascular surgeon at the Hospital of the University of Pennsylvania and has experience with the original Pounce System. She recently deployed the Pounce LP device to revascularize a patient with arterial occlusions in both the anterior tibial and peroneal arteries.
 
“The Pounce LP System allowed me to treat chronic thrombus in these vessels with the effectiveness I’d expect from open surgical Fogarty embolectomy while maintaining the advantages of an endovascular approach for treating underlying and distal disease,” Genovese told the press. “We were able to achieve an optimal outcome in a very complex lesion, and this type of result would not have been possible without this device.”
 
Surmodics president and CEO Gary Maharaj said, “We’re very pleased with the successful early clinical use of the Pounce LP Thrombectomy System, which will extend the range of treatment for our Pounce platform to include removal of organized thrombotic or embolic clots from the iliac arteries in the pelvis down to tibial vessels below the knee. Downstream embolization of chronic material into below-the-knee arteries during an endovascular procedure can be an interventionist’s nightmare, sometimes requiring surgical rescue. The Pounce LP System’s ability to capture and remove these unexpected emboli adds yet more value to this device for BTK revascularization.”